Breath Diagnostics, Inc. is a Louisville, Kentucky-based company formed in October 2014 to bring to market its revolutionary technology, which tests a patient’s exhaled breath for cancer specific markers. The company’s mission is to globally implement breath analysis technology to provide early cancer detection and reduce patient exposure to costly, high-risk medical procedures.
The corporate objective is to launch OneBreath for LC diagnosis and ultimately expand the use of the technology into breath tests for other applications, including other cancers and diseases. The first objective is to complete FDA enabling trials. The company will develop its corporate footprint in collaboration with one or more CLIA certified labs, which will serve as a partner in the development of BDx’s technology, as an investor, and as an initial production and distribution partner.